LUNAR study: Latanoprostene bunod non-inferior to timolol over 3 months

Latanoprostene bunod was shown to be non-inferior to timolol in treating patients with open-angle glaucoma or ocular hypertension, according to results of the LUNAR study.In addition, latanoprostene bunod reduced IOP significantly more than timolol at all but the earliest time points evaluated.